Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

December 18, 2024

Replay: KOL insights and MaaT013 Data from ASH 2024 Meeting

December 11, 2024

December 10, 2024: France’s MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD – a formal study will read out early next year – Biotech TV

December 10, 2024

December 10, 2024: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

Like what you see? See more posts

Our upcoming events

Event
December 3, 2024

35th International Symposium on ALS/MND

• December 6-8, 2024 – International Symposium on ALS/MND
MaaT Pharma
Event
December 3, 2024

ASH Annual Meeting and Exposition

• December 7-10, 2024 – 66th ASH Annual Meeting and Exposition
MaaT Pharma
Event
November 20, 2024

JP Morgan – 2025 Healthcare Conference

• January 13-16, 2025 – JP Morgan, Healthcare Conference
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers